Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Chimeric Therapeutics
Its shares trade on ASX under the ticker CHM.AX. It has been listed since 18 January 2021. In the fiscal year to 30 June 2025, it reported revenue of A$4.0m and a net loss of A$10.4m. At that date it held total assets of A$21.6m and shareholders' equity of A$2.0m.
Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase I clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The firm is also focused on the development of four NK and CAR NK assets with plans for Phase I clinical trials in solid tumors and blood cancers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Jan 2021
- Website
- chimerictherapeutics.com ↗
Leadership
Pay as last reported
- Mr. Paul HopperExecutive Chairman of the Board, Founder, since 2020A$332,500
- Mr. Phillip HainsChief Financial Officer, Joint Company Secretary, Director, since 2020
- Dr. Rebecca McqualterChief Operating Officer
- Dr. Eliot BourkChief Business OfficerA$1.3m
- Dr. Jason LittenChief Medical Officer
- Mr. Nathan JongJoint Company Secretary
- Prof. H. Miles PrinceNon-Executive Director
- Dr. Lesley RussellNon-Executive DirectorA$131,042
- Mr. Eric SullivanNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Chlorotixin CAR-T technology targets solid tumors with CHM 1101 in Phase I trials for glioblastoma.
- Chimeric Therapeutics has a pipeline including CHM 2101 and CORE-NK platform for multiple cancer types.
- The company focuses on cell therapies for cancer patients with four NK and CAR NK assets in development.
Weaknesses
- Chimeric Therapeutics' CHM 1101 is only in Phase I clinical trial for glioblastoma.
- The company has no commercialized products yet as CHM 2101 remains in preclinical development.
- Chimeric Therapeutics' pipeline lacks Phase III trials for any product in development.
Opportunities
- Chimeric Therapeutics can expand its pipeline with CHM 2101 targeting neuroendocrine tumors and colorectal cancer.
- The CORE-NK platform offers off-the-shelf NK cell therapy for solid tumors and blood cancers.
- Chimeric Therapeutics may benefit from growing demand for cell therapies in the Health Care sector.
Threats
- Chimeric Therapeutics faces competition from other biotechnology firms in CAR-T therapy development.
- The company's reliance on clinical trial success for CHM 1101 and CHM 2101 poses significant risk.
- Regulatory hurdles in the Health Care industry could delay product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.